Dementia Cases in the U.S. Will Surge in the Coming Decades, Researchers Say
The New York Times
By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a study predicts.
The number of people in the United States who develop dementia each year will double over the next 35 years to about one million annually by 2060, a new study estimates, and the number of new cases per year among Black Americans will triple.
The increase will primarily be due to the growing aging population, as many Americans are living longer than previous generations. By 2060, some of the youngest baby boomers will be in their 90s and many millennials will be in their 70s. Older age is the biggest risk factor for dementia. The study found that the vast majority of dementia risk occurred after age 75, increasing further as people reached age 95.
The study, published Monday in Nature Medicine, found that adults over 55 had a 42 percent lifetime risk of developing dementia. That is considerably higher than previous lifetime risk estimates, a result the authors attributed to updated information about Americans’ health and longevity and the fact that their study population was more diverse than that of previous studies, which have had primarily white participants.
Some experts said the new lifetime risk estimate and projected increase in yearly cases could be overly high, but they agreed that dementia cases would soar in the coming decades.
“Even if the rate is significantly lower than that, we’re still going to have a big increase in the number of people and the family and societal burden of dementia because of just the growth in the number of older people, both in the United States and around the world,” said Dr. Kenneth Langa, a professor of medicine at the University of Michigan, who has researched dementia risk and was not involved in the new study.
Dementia already takes an enormous toll on American families and the country’s health care system. More than six million Americans currently have dementia, nearly 10 percent of people 65 and older, research has found. Experts say that each year in the United States, dementia causes more than 100,000 deaths and accounts for more than $600 billion in caregiving and other costs.
Despite the lack of big names or critical hype, the romance adaptation “Virgin River” has been one of Netflix’s biggest, most reliable successes.
A “red alert” involving the private Blue Ghost mission in lunar orbit a year ago highlights a growing number of incidents above Earth’s neighbor.
The tech giant pushed back the timeline after spending billions to be on the cutting edge of artificial intelligence.
Practitioners nationwide are striving to do what’s best for children’s health, while staying supportive in the face of mistrust and confusion.
A group of scientists and law enforcement officials are pointing to the role moss can play to help solve crimes.
Blaming chatbots, they are joining an earlier push for better protections by parents who say social media contributed to their children’s deaths.
Partula snails all but vanished from Polynesia after the arrival of a carnivorous foreign snail. But a global alliance of zoos has worked to bring them back.
Though high rates of the disease persist among the nearby Indigenous communities, the Canadian government is weighing rules that may allow energy giants to release treated mining waste into the river system.
A new study offers clues as to how the insects survive flooding as they emerge from a hibernation-like phase every winter.
Scientists studied centuries-old bird feathers from an ancient tomb on the coast, and then traced the origins back to the Amazon.
Blaming chatbots, they are joining an earlier push for better protections by parents who say social media contributed to their children’s deaths.
The agency is proposing allowing other tastes for vapes, like mint, coffees, spices or tea, to appeal to adults. At the same time, illicit candy-flavored types aimed at teenagers have flooded the market.
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.